Is there scope for better individualisation of anthracycline cancer chemotherapy?

Anthracyclines are used to treat solid and haematological cancers, particularly breast cancers, lymphomas and childhood cancers. Myelosuppression and cardiotoxicity are the primary toxicities that limit treatment duration and/or intensity. Cardiotoxicity, particularly heart failure, is a leading cau...

Full description

Bibliographic Details

Published in:	British journal of clinical pharmacology Vol. 87; no. 2; pp. 295 - 305
Main Authors:	Sallustio, Benedetta C., Boddy, Alan V.
Format:	Journal Article
Language:	English
Published:	England 01.02.2021
Subjects:	anthracycline cancer cardiotoxicity individualised therapy pharmacogenetics pharmacokinetics pharmacokinetics cardiotoxicity cancer anthracycline pharmacogenetics individualised therapy
ISSN:	0306-5251, 1365-2125, 1365-2125
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!